While acknowledged oncogenic drivers, such as EGFR, ALK, ROS1, and BRAF, have a solid role in the therapeutic algorithms for advanced NSCLC, other actionable targets are progressively being identified, and novel targeted antineoplastic agents are being developed. Here, BRAF is linked to non-small cell lung carcinoma.